Fritextsökning
Artiklar per år
Innehållstyper
-
“You discover one thing – and then 10 new questions arise”
COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current focus is on her next field: the role of gut flora in human health.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Opioidtablett på villovägar stoppar hel leverans av hjärtmedicin
Ett förlupet opioidpiller har tvingat amerikanska KVK Tech att av säkerhetsskäl återkalla en hel batch med hjärtläkemedel.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
Sweden Bio: ”EU-förslag rycker undan mattan för investeringar”
”Lagförslaget går stick i stäv med sitt eget syfte”, skriver Sweden Bios vd Jessica Martinsson i en debattartikel om förslaget om en ny läkemedelslagstiftning för EU:s medlemsländer.
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve been in the thick of things and part of the development for so long now, but I’m also looking forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden
-
Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study
In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one of the most extensive studies in the world currently being conducted for a drug for post-COVID.
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Director at a biotech company. “I’m curious and like to have influence, so I’ve often chosen management roles,” she says.
-
Synact nådde inte målen i studie: ”Vi är besvikna”
Lundbaserade Synact Pharma nådde inte sitt primära mål i fas IIb-studien Expand, där läkemedelskandidaten resomelagon utvärderades för patienter med svår aktiv nydiagnostiserad reumatoid artrit. Beskedet fick bolagets aktie att falla kraftigt.
-
Ascelia halverar arbetsstyrkan – ”Tyvärr är dessa steg nödvändiga”
Bioteknikbolaget Ascelia Pharma säger upp tolv personer - nästan halva arbetsstyrkan - för att minska kostnaderna sedan delar av en studie måste göras om. ”Detta är ett mycket svårt beslut för oss att ta”, säger vd:n Magnus Corfitzen.
-
Fortsatt ökning av läkemedelsexporten
Läkemedel fortsätter att bli en allt viktigare exportprodukt för Sverige, visar färska siffror från Statistiska Centralbyrån, SCB.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list that aims to promote sustainable entrepreneurship.
-
Här är life science-företagen på Norrskens lista – ”Ett Nobelpris för entreprenörer”
Små robotar som levererar läkemedel till olika delar av kroppen. Det är ett av projekten som är med på Norrskens Impact 100-lista.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says Helena Lüning of the industry organisation ASCRO.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Departmental Secretary at the office, about the ongoing work.
-
Neanderthal gene variants may cause Viking disease
A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.
-
Attgeno stärker kassan för fortsatt fas II-studie med kväveoxid
Bioteknikbolaget Attgeno, som utvecklar ett läkemedel mot akut pulmonell hypertension (APH), har genomfört en riktad nyemission till befintliga aktieägare som tillför bolaget 12 miljoner kronor.
-
Studie: Taurin gav längre livslängd för djur
Möss, ormar och apor som fick aminosyran taurin under en längre tid uppvisade mindre åldersrelaterade tecken än kontrollgrupper, enligt en studie.
-
Norwegian company wins bidding battle for Sensidose
The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and leaving the way open for Norwegian company Navamedic.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
-
Klartecken för kliniska studier av Eliceras CAR T-terapi
Göteborgsbaserade Elicera Therapeutics har fått klartecken för att inleda den första kliniska utvärderingen av företagets CAR T-cellsbehandling mot B-cellslymfom.
BREAKING